Wan‐Teck Lim

14.1k total citations · 2 hit papers
212 papers, 6.2k citations indexed

About

Wan‐Teck Lim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Wan‐Teck Lim has authored 212 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 123 papers in Oncology, 111 papers in Pulmonary and Respiratory Medicine and 40 papers in Molecular Biology. Recurrent topics in Wan‐Teck Lim's work include Lung Cancer Treatments and Mutations (94 papers), Lung Cancer Research Studies (33 papers) and Head and Neck Cancer Studies (30 papers). Wan‐Teck Lim is often cited by papers focused on Lung Cancer Treatments and Mutations (94 papers), Lung Cancer Research Studies (33 papers) and Head and Neck Cancer Studies (30 papers). Wan‐Teck Lim collaborates with scholars based in Singapore, United States and China. Wan‐Teck Lim's co-authors include Chwee Teck Lim, Daniel Shao-Weng Tan, Chee‐Keong Toh, Ali Asgar S. Bhagat, Jongyoon Han, Majid Ebrahimi Warkiani, Eng-Huat Tan, Ross A. Soo, Bee Luan Khoo and Swee Jin Tan and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Nature Communications.

In The Last Decade

Wan‐Teck Lim

197 papers receiving 6.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Isolation and retrieval of circulating tumor cells using centrifugal forces

2013 595 citations Han Wei Hou, Ross A. Soo et al. profile →
Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells

2013 472 citations Daniel Shao-Weng Tan, Wan‐Teck Lim et al. profile →

Peers

Countries citing papers authored by Wan‐Teck Lim

Since Specialization

Citations

This map shows the geographic impact of Wan‐Teck Lim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wan‐Teck Lim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wan‐Teck Lim more than expected).

Fields of papers citing papers by Wan‐Teck Lim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wan‐Teck Lim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wan‐Teck Lim. The network helps show where Wan‐Teck Lim may publish in the future.

Co-authorship network of co-authors of Wan‐Teck Lim

This figure shows the co-authorship network connecting the top 25 collaborators of Wan‐Teck Lim. A scholar is included among the top collaborators of Wan‐Teck Lim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wan‐Teck Lim. Wan‐Teck Lim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A misdiagnosed case of shoulder pigmented villonodular synovitis – A case report 2025 ·Journal of Orthopaedic Reports ·(unknown), Wan‐Teck Lim, Denny Lie, Henry Soeharno	0
2	Assessment of Quality of Life in Advanced-Stage Lung Cancer Patients Using EORTC QLQ-C30 Questionnaire 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Wan‐Teck Lim	0
3	Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC 2024 ·Lung Cancer ·Stephanie P.L. Saw, (unknown), Gillianne Lai, Landon L. Chan, (unknown), (unknown), (unknown), (unknown), (unknown), Aaron C. Tan, (unknown), (unknown), (unknown), Quan Sing Ng, Mei‐Kim Ang, Ravindran Kanesvaran, Wan‐Teck Lim, Daniel S.W. Tan, Tony Mok, (unknown)	4
4	High-Throughput Microfluidic Extraction of Platelet-free Plasma for MicroRNA and Extracellular Vesicle Analysis 2024 ·ACS Nano ·(unknown), (unknown), (unknown), (unknown), Hui Min Tay, (unknown), Fang Kong, (unknown), Wei Wang, Enkhtuya Radnaa, Ramkumar Menon, Ming Dao, Rinkoo Dalan, Subra Suresh, Wan‐Teck Lim, Han Wei Hou	11
5	Magnetic augmentation through multi-gradient coupling enables direct and programmable profiling of circulating biomarkers 2024 ·Nature Communications ·(unknown), (unknown), Xingjie Wu, Xuecheng Sun, (unknown), (unknown), Auginia Natalia, John Kit Chung Tam, Wan‐Teck Lim, Balram Chowbay, Beng Ti Ang, Carol Tang, Tze Ping Loh, Huilin Shao	5
6	Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC). 2024 ·Journal of Clinical Oncology ·Qiuyan Chen, Hai‐Qiang Mai, Dongping Chen, Chaosu Hu, Kunyu Yang, Jiyu Wen, Jingao Li, (unknown), Feng Jin, (unknown), Jianji Pan, Shenhong Qu, (unknown), Chunhong Hu, Yi‐Chun Liu, Yi Jiang, Xia He, Hung‐Ming Wang, Wan‐Teck Lim, Rui‐Hua Xu, (unknown)	2
7	Combinatorial hypofractionated radiotherapy and pembrolizumab in anaplastic thyroid cancer 2024 ·European Thyroid Journal ·(unknown), Timothy Kwang Yong Tay, Enya H.W. Ong, Michael Fehlings, Daniel Shao-Weng Tan, (unknown), (unknown), (unknown), (unknown), (unknown), Wan‐Teck Lim, N. Gopalakrishna Iyer, Jacqueline Siok Gek Hwang, Melvin L.K. Chua, Mei‐Kim Ang	8
8	A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma 2023 ·Targeted Oncology ·Albiruni Ryan Abdul Razak, Hung‐Ming Wang, Jang‐Yang Chang, Myung‐Ju Ahn, Pamela N. Münster, George R. Blumenschein, Benjamin Solomon, Wan‐Teck Lim, Ruey‐Long Hong, David G. Pfister, Nabil F. Saba, Se‐Hoon Lee, Carla van Herpen, Cornelia Quadt, Douglas Bootle, Lars Blumenstein, David Demanse, Jean‐Pierre Delord	10
9	Molecular testing in non-small cell lung cancer: A consensus recommendation 2023 ·Annals of the Academy of Medicine Singapore ·Gillianne Lai, Xin Cheng, Yvonne Ang, Kevin Lee Min Chua, Jens Samol, Ross A. Soo, Daniel S.W. Tan, Tony Kiat Hon Lim, Wan‐Teck Lim	0
10	1046P Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results 2023 ·Annals of Oncology ·Hong Jiang, B-Y. Ryoo, Maxime Chénard-Poirier, (unknown), Wan‐Teck Lim, Jens Samol, Giovanni Abbadessa, Robin Meng, Serena Masciari, (unknown), Yan Zhang, (unknown), (unknown), (unknown), (unknown)	5
11	Longitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinoma 2023 ·Oral Oncology ·(unknown), (unknown), Enya H.W. Ong, Jingjing Miao, (unknown), Joseph Wee, Kam Weng Fong, Yoke Lim Soong, (unknown), (unknown), (unknown), Jianjun Liu, Kwok Seng Loh, Joshua K. Tay, Mei‐Kim Ang, Sze Huey Tan, Wan‐Teck Lim, Melvin L.K. Chua	10
12	Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC 2023 ·Biomedicines ·(unknown), (unknown), Su Chin Tham, Wan‐Teck Lim	11
13	Analysis of T cell receptor clonotypes in tumor microenvironment identifies shared cancer-type-specific signatures 2021 ·Cancer Immunology Immunotherapy ·(unknown), (unknown), Lisda Suteja, João M.L. Dias, Annalisa Mupo, Rachael Bashford-Rogers, George S. Vassiliou, Melvin L.K. Chua, Daniel S.W. Tan, Wan‐Teck Lim, N. Gopalakrishna Iyer	8
14	Phase II study of nimotuzumab (TheraCim‐hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma 2021 ·Head & Neck ·Mei‐Kim Ang, (unknown), Ekkasit Tharavichitkul, Cindy Lim, Terence Tan, (unknown), Joseph Wee, Yoke Lim Soong, (unknown), Quan Sing Ng, (unknown), Chee‐Keong Toh, (unknown), Wan‐Teck Lim	10
15	Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation 2021 ·Lung Cancer ·Keunchil Park, Gee‐Chen Chang, Giuseppe Curigliano, Wan‐Teck Lim, Ross A. Soo, Miguel Ángel Molina‐Vila, Valérie Cattan, (unknown), (unknown), (unknown), (unknown), Santiago Viteri	10
16	Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC) 2019 ·PLoS ONE ·(unknown), Sze Huey Tan, Wan‐Teck Lim, Eng Huat Tan, Quan Sing Ng, Kiattisa Sommat, Daniel S.W. Tan, Mei‐Kim Ang	21
17	Real world data on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) use in advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR mutations in Singapore 2018 ·Annals of Oncology ·(unknown), E.H. Tan, Wan‐Teck Lim, Mei‐Kim Ang, Daniel Shao-Weng Tan, Quan Sing Ng, (unknown), Amit Jain, (unknown), Chee‐Keong Toh, Tanujaa Rajasekaran	5
18	18^F-fluoro-2-deoxyglucose uptake on PET CT and glucose transporter 1 expression in colorectal adenocarcinoma 2012 ·世界胃肠病学杂志：英文版 ·Hồng, (unknown), Wan‐Teck Lim	3
19	Electroacupuncture for Refractory Acute Emesis Caused by Chemotherapy 2006 ·The Journal of Alternative and Complementary Medicine ·Su Pin Choo, Keng-He Kong, Wan‐Teck Lim, Fei Gao, Karen Sui Geok Chua, Swan-Swan Leong	18
20	Primary basal cell carcinoma of the middle ear presenting as recurrent cholesteatoma. 1999 ·PubMed ·Wan‐Teck Lim, Christopher Danner, (unknown), (unknown), (unknown), (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact